Evidence map›Paper›PMID 34176159›Full record

ArticleProteins2021

RosettaCM for antibodies with very long HCDR3s and low template availability.

Pranav Kodali, Clara T Schoeder, Samuel Schmitz, James E Crowe, Jens Meiler

Open access · greenAbstract read
In one paragraph

Article in Proteins, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. VInternational journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Pranav KodaliDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.ORCID 0000-0003-0861-1722
Clara T SchoederDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.ORCID 0000-0002-4664-961X
Samuel SchmitzDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.ORCID 0000-0001-5314-6095
James E CroweVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-0049-1079
Jens MeilerDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.ORCID 0000-0001-8945-193X
Vanderbilt University · USVanderbilt University Medical Center · US

Funding

Structure based design of antibodies and vaccinesU19AI117905 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E · 2015 to 2019
$12.0M
ROSETTA An Integrated Protein Structure Modeling SuiteR01GM073151 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KUHLMAN, BRIAN A · 2005 to 2019
$7.8M
Structure based design of trimer interface epitope focused universal influenza vaccinesU01AI150739 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E · 2020 to 2024
$6.1M
Epitope-Based Design and Modified RNA Platform for Bivalent Marburgvirus VaccineR01AI141661 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BUKREYEV, ALEXANDER, CROWE, JAMES E · 2019 to 2023
$3.9M
Structural Determinants of Allosteric Modulation of Brain GPCRsR01DA046138 · NIDA · VANDERBILT UNIVERSITY · PI MEILER, JENS · 2019 to 2023
$2.0M
High-Performance Computer Cluster for Biomedical ResearchS10OD023680 · OD · VANDERBILT UNIVERSITY · PI MEILER, JENS · 2017 to 2017
$587k
Hybrid Methods for Prediction and Design of Novel Human Influenza AntibodiesR56AI110750 · NIAID · VANDERBILT UNIVERSITY · PI CROWE, JAMES E, MEILER, JENS · 2014 to 2014
$433k
NIAID NIH HHS R01 AI141661NIAID NIH HHS R56 AI110750NIAID NIH HHS U01 AI150739NIAID NIH HHS U19 AI117905NIDA NIH HHS R01 DA046138NIGMS NIH HHS R01 GM073151NIH HHS S10 OD023680
6 · The paper itself

Abstract

Antibody-antigen co-crystal structures are a valuable resource for the fundamental understanding of antibody-mediated immunity. Determination of structures with antibodies in complex with their antigens, however, is a laborious task without guarantee of success. Therefore, homology modeling of antibodies and docking to their respective antigens has become a very important technique to drive antibody and vaccine design. The quality of the antibody modeling process is critical for the success of these endeavors. Here, we compare different computational protocols for predicting antibody structure from sequence in the biomolecular modeling software Rosetta-all of which use multiple existing antibody structures to guide modeling. Specifically, we compare protocols developed solely to predict antibody structure (RosettaAntibody, AbPredict) with a universal homology modeling protocol (RosettaCM). Following recent advances in homology modeling with multiple templates simultaneously, we propose that the use of multiple templates over the same antibody regions may improve modeling performance. To evaluate whether multi-template comparative modeling with RosettaCM can improve the modeling accuracy of antibodies over existing methods, this study compares the performance of the three modeling algorithms when modeling human antibodies taken from antibody-antigen co-crystal structures. In these benchmarking experiments, RosettaCM outperformed other methods when modeling antibodies with long HCDR3s and few available templates.

Indexed as

AlgorithmsSoftwareStructural Homology, ProteinAntibodiesAntigen-Antibody ComplexAntigensBenchmarkingDatabases, ProteinHumansMolecular Docking SimulationMolecular Dynamics SimulationProtein ConformationAntibodiesAntigen-Antibody ComplexAntigensantibodybenchmarkhomology modelingloop predictionRosettastructure

Identifiers

PMID34176159
PMCPMC8492515
OpenAlexW3176087863

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.